AZmed

AZmed is a French medical technology company headquartered in Paris that develops artificial intelligence software for medical imaging. Its products are organized into two suites: Rayvolve, an AI suite for X-rays, and Rayscan, an AI suite for CT. Rayvolve comprises AZtrauma for detection of fractures, dislocations, joint effusions and other bone and joint lesions; AZchest for categorization, detection and reporting of the main cardiac and lung abnormalities on chest X-rays; AZmeasure for automated characterization of osteo-articular angles and lengths; and AZboneage for pediatric bone age assessment from hand X-rays using the Greulich and Pyle method. Rayscan includes AZnod, for detection, characterization and 3D volumetric measurement of lung nodules on chest CT.

The software is positioned as a second-read, triage and reporting layer that runs inside existing radiology workflows and integrates with PACS/RIS systems and viewers. The company states its products are CE-marked (Class IIa) and FDA-cleared, developed under ISO 13485 and MDSAP-certified quality systems, and delivered on infrastructure described as SOC 2 Type II, GDPR- and HIPAA-compliant, with ENS Alto certification. AZmed reports more than 10 publications and over 30 studies and validations conducted with academic institutions, with results appearing in journals including Academic Radiology, Journal of Imaging and Pediatric Radiology.

As of 2026 the company reports deployment at more than 2,500 sites in over 55 countries and more than 15.3 million X-rays analyzed in the preceding 12 months. Its team is described on the company site as 50+ members of 10+ nationalities; a third-party business data provider estimated roughly 103 employees and annual revenue in the $1M-$10M range as of August 2026.

Founding story

AZmed was founded in 2018 by Julien Vidal (CEO), Alexandre Attia (CTO) and Dr Elie Zerbib-Attal (CMO) with the stated aim of optimizing physicians' workflows and extending their capabilities with artificial intelligence, so that radiologists have tools that match the pace of their work.

Business model

AZmed sells AI diagnostic-support software to healthcare institutions, with products offered as modules (AZtrauma, AZchest, AZmeasure, AZboneage, AZnod) that can be adopted individually or as full suites and deployed into a customer's existing PACS/RIS and viewer environment.

Revenue comes from supplying imaging AI software to healthcare institutions; a third-party data provider estimated annual revenue in the $1M-$10M range as of August 2026.

Traction

More than 15.3 million X-rays analyzed in a 12-month period, 2,500+ deployed sites, 55+ countries, 10+ publications and 30+ studies and validations, and eight FDA-cleared Rayvolve findings following a sixth FDA clearance in 2026.

Latest developments

In September 2026 AZmed announced its sixth FDA clearance, bringing Rayvolve to eight FDA-cleared findings across musculoskeletal and chest X-rays. In May 2026 it announced a partnership with Radin Health aimed at enhancing radiology workflow. The Rayscan CT suite is active with AZnod for lung nodules, and additional CT solutions are described as under development.